Using Xanthohumol to help treat septic shock
Analysis of Anti-inflammatory Effect of Hop Extract Rich in Xanthohumol in Patients Treated for Septic Shock
PHASE2 · Medical University of Lublin · NCT06225258
This study is testing if a natural compound called Xanthohumol can help improve recovery for patients with septic shock who need breathing support.
Quick facts
| Phase | PHASE2 |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Medical University of Lublin (other) |
| Locations | 1 site (Lublin, Lublin Voivodeship) |
| Trial ID | NCT06225258 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the use of Xanthohumol as an adjuvant treatment for patients experiencing septic shock, a severe condition characterized by an overwhelming inflammatory response to infections. The study focuses on patients in the early acute phase of septic shock who require mechanical ventilation due to respiratory insufficiency. By targeting the inflammatory response and cytokine release associated with septic shock, the trial aims to improve organ function and patient outcomes. Participants will be closely monitored in an intensive care unit setting to assess the effectiveness of the intervention.
Who should consider this trial
Good fit: Ideal candidates for this study are adults in the early phase of septic shock with respiratory insufficiency requiring mechanical ventilation and specific inflammatory markers.
Not a fit: Patients with a history of severe chronic cardiac, pulmonary, or liver diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve recovery rates and organ function in patients suffering from septic shock.
How similar studies have performed: Previous studies have shown promise in reducing inflammatory responses in septic shock, suggesting that this approach may be beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * a septic shock in the early, acute phase, * respiratory insufficiency required mechanical ventilation with PaO2/FiO2 \< 150, * bacterial infection, * procalcitonin higher than 5 ng/mL and interleukin 6 higher than 100 pg/mL, * no allergy to hops or their derivatives, * hemodynamic instability requiring vasopressor infusions Exclusion Criteria: * lack of agreement * septic shock treated for more than 1 day, * history of severe chronic cardiac, pulmonary and/or liver diseases
Where this trial is running
Lublin, Lublin Voivodeship
- Intensive Care Unit, University Hospital No 4, — Lublin, Lublin Voivodeship, Poland (RECRUITING)
Study contacts
- Principal investigator: Wlodzimierz Plotek — Medical University of Lublin, Poland
- Study coordinator: Wojciech Dabrowski, Prof
- Email: wojciech.dabrowski@umlub.pl
- Phone: +48604241040
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Septic Shock, Pneumonia, ARDS, septic shock, inflammation, Xanthohumol, adjuvant, endotheliopathy